Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells-Report on Two Cases.
Gerhardt K, Jentzsch M, Georgi T, Sretenović A, Cross M, Bach E, Monecke A, Leiblein S, Hoffmann S, Todorović M, Bila J, Sabri O, Schwind S, Franke GN, Platzbecker U, Vučinić V. Gerhardt K, et al. Among authors: vucinic v. Front Oncol. 2021 Sep 16;11:737645. doi: 10.3389/fonc.2021.737645. eCollection 2021. Front Oncol. 2021. PMID: 34604075 Free PMC article.
Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study.
Schubert ML, Bethge WA, Ayuk FA, von Bonin M, Vucinic V, Wagner-Drouet EM, Subklewe M, Baldus CD, Glass B, Marks R, Mougiakakos D, Schroers R, Stelljes M, Topp MS, Wulf G, Kröger N, Dreger P. Schubert ML, et al. Among authors: vucinic v. Blood Adv. 2023 Oct 24;7(20):6191-6195. doi: 10.1182/bloodadvances.2023011203. Blood Adv. 2023. PMID: 37603595 Free PMC article. No abstract available.
Low tumor burden is associated with early B-cell reconstitution and is a predictor of favorable outcome after non-myeloablative stem cell transplant for chronic lymphocytic leukemia.
Hebenstreit K, Iacobelli S, Leiblein S, Eisfeld AK, Pfrepper C, Heyn S, Vucinic V, Franke GN, Krahl R, Fricke S, Becker C, Pönisch W, Behre G, Niederwieser D, Lange T. Hebenstreit K, et al. Among authors: vucinic v. Leuk Lymphoma. 2014 Jun;55(6):1274-80. doi: 10.3109/10428194.2013.836598. Epub 2013 Oct 3. Leuk Lymphoma. 2014. PMID: 23964650
Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma.
Poenisch W, Plötze M, Holzvogt B, Andrea M, Schliwa T, Zehrfeld T, Hammerschmidt D, Schwarz M, Edelmann T, Becker C, Hoffmann FA, Schwarzer A, Kreibich U, Gutsche K, Reifenrath K, Schwarzbach H, Heyn S, Franke GN, Jentzsch M, Leiblein S, Schwind S, Lange T, Vucinic V, AlAli HK, Niederwieser D. Poenisch W, et al. Among authors: vucinic v. J Cancer Res Clin Oncol. 2015 Nov;141(11):2013-22. doi: 10.1007/s00432-015-1984-4. Epub 2015 May 15. J Cancer Res Clin Oncol. 2015. PMID: 25976868
Prognostic impact of the CD34+/CD38- cell burden in patients with acute myeloid leukemia receiving allogeneic stem cell transplantation.
Jentzsch M, Bill M, Nicolet D, Leiblein S, Schubert K, Pless M, Bergmann U, Wildenberger K, Schuhmann L, Cross M, Pönisch W, Franke GN, Vucinic V, Lange T, Behre G, Mrózek K, Bloomfield CD, Niederwieser D, Schwind S. Jentzsch M, et al. Among authors: vucinic v. Am J Hematol. 2017 Apr;92(4):388-396. doi: 10.1002/ajh.24663. Epub 2017 Feb 21. Am J Hematol. 2017. PMID: 28133783 Free article.
Prognostic impact of the European LeukemiaNet standardized reporting system in older AML patients receiving stem cell transplantation after non-myeloablative conditioning.
Bill M, Jentzsch M, Grimm J, Schubert K, Lange T, Cross M, Behre G, Vucinic V, Pönisch W, Franke GN, Niederwieser D, Schwind S. Bill M, et al. Among authors: vucinic v. Bone Marrow Transplant. 2017 Jun;52(6):932-935. doi: 10.1038/bmt.2017.42. Epub 2017 Apr 3. Bone Marrow Transplant. 2017. PMID: 28368377 Clinical Trial. No abstract available.
Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV).
Tessenow H, Holzvogt M, Holzvogt B, Andrea M, Heyn S, Schliwa T, Schwarz M, Zehrfeld T, Becker C, Pfrepper C, Franke GN, Krahl R, Jentzsch M, Leiblein S, Schwind S, Bill M, Vucinic V, Lange T, Niederwieser D, Pönisch W. Tessenow H, et al. Among authors: vucinic v. J Cancer Res Clin Oncol. 2017 Oct;143(10):2049-2058. doi: 10.1007/s00432-017-2439-x. Epub 2017 May 22. J Cancer Res Clin Oncol. 2017. PMID: 28534173
Inversion 3 Cytogenetic Abnormality in an Allogeneic Hematopoietic Cell Transplant Recipient Representative of a Donor-Derived Constitutional Abnormality.
Dias A, Al-Kali A, Van Dyke D, Niederwieser D, Vucinic V, Lemke J, Muller C, Schwind S, Teichmann AC, Bakken R, Burns LJ, Litzow M. Dias A, et al. Among authors: vucinic v. Biol Blood Marrow Transplant. 2017 Sep;23(9):1582-1587. doi: 10.1016/j.bbmt.2017.05.019. Epub 2017 May 23. Biol Blood Marrow Transplant. 2017. PMID: 28549770 Free article.
High BAALC copy numbers in peripheral blood prior to allogeneic transplantation predict early relapse in acute myeloid leukemia patients.
Jentzsch M, Bill M, Grimm J, Schulz J, Goldmann K, Beinicke S, Häntschel J, Pönisch W, Franke GN, Vucinic V, Behre G, Lange T, Niederwieser D, Schwind S. Jentzsch M, et al. Among authors: vucinic v. Oncotarget. 2017 Sep 27;8(50):87944-87954. doi: 10.18632/oncotarget.21322. eCollection 2017 Oct 20. Oncotarget. 2017. PMID: 29152132 Free PMC article.
125 results